查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951263

丙型肝炎市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、治療方法、診斷、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年）

Hepatitis C Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Diagnosis, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球丙型肝炎市場預計將從 2025 年的 93.2 億美元成長到 2031 年的 131.5 億美元，年複合成長率為 5.91%。

此業務板塊涵蓋診斷工具和治療藥物的生產和分銷，主要包括用於治療和根除丙型肝炎病毒感染的直接抗病毒藥物（DAA）。市場成長的主要促進因素是全球疾病負擔的加重以及國際上關於病毒根除的指南，這些因素正在推動政府主導的篩檢和治療計畫。此外，現代抗病毒療法的安全性和高成功率提高了患者的依從性，擴大了治療目標族群，以滿足世界衛生組織（WHO）報告的2024年5000萬慢性丙型肝炎患者的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 93.2億美元
市場規模：2031年 131.5億美元
複合年成長率：2026-2031年 5.91%
成長最快的細分市場 慢性C型肝炎
最大的市場 北美洲

儘管有這些積極跡象，但由於先進治療方法的高昂費用限制了價格敏感型開發中國家的醫療資源獲取，市場仍面臨許多障礙。低診斷率進一步加劇了這一經濟障礙，醫療基礎設施不足導致無症狀感染者難以被發現。因此，許多感染者未能得到治療，阻礙了市場充分發揮潛力，並延緩了全球根除疫情的努力。

市場促進因素

政府主導的疾病消除計畫的實施是推動各國推動與全球衛生目標相符策略的關鍵市場催化劑。此類大規模公共衛生系統需要大量採購診斷試劑和藥品，為產業相關人員建立穩健的商業管道。英國在這方面取得了成功，證明了國家主導工作的有效性。根據病毒性肝炎預防委員會於2024年11月發布的《2024年英格蘭丙型肝炎報告》中的分析，英國的國家消除策略將丙型肝炎相關死亡率降低至每10萬人0.41例，超過了世界衛生組織（世衛組織）的目標，這充分體現了資助干預措施的價值。

在這些政策的配合下，先進的直接抗病毒療法（DAA）的廣泛應用使得確診患者能夠得到快速有效的治療，從而推動了市場擴張。這些現代治療方法具有卓越的安全性，且給藥方案簡化，顯著提高了治療的可近性，並促使全球治療人數增加。英國肝臟信託基金會於2025年4月發布的《2024年英格蘭丙型肝炎報告》強調了這一日益成長的需求，該報告指出，96.1%的確診患者已開始接受治療。然而，全球疾病負擔仍是推動需求的主要因素。美國疾病管制與預防中心（CDC）於2025年7月發布的《全球病毒性肝炎》最新報告顯示，前一年全球約有100萬例新增感染病例，凸顯了市場對解決方案的持續需求。

市場挑戰

先進抗病毒療法的高昂採集費用嚴重阻礙因素了市場成長，尤其是在醫療資源有限的開發中國家。這些高定價模式往往超出公共醫療系統和個人患者的承受能力，從而限制了治療的可及性。這些經濟壁壘阻礙了市場利用該地區高發病率的機會，導致在急需醫療干預的地區出現重大商機損失和市場准入受限。

此外，醫療基礎設施的匱乏加劇了這項挑戰，阻礙了對感染者的識別。診斷能力的不足導致大量患者不了解自身感染狀況，也無法獲得所需的治療。世界衛生組織（世衛組織）預測，到2024年，全球僅有36%的C型肝炎感染者能夠確診。如此巨大的診斷缺口有效地縮小了潛在市場規模，直接阻礙了市場的整體擴張，因為大多數潛在的治療候選人仍未被發現和治療。

市場趨勢

將醫療服務下放至社區藥局正在改變服務提供方式，將治療啟動從中心化醫院轉移到當地社區藥局。這一趨勢有助於克服基礎設施的限制，使藥劑師能夠篩檢和開立直接抗病毒藥物，從而有效地接觸到那些在傳統醫療路徑中常常被忽略的患者。美國國立衛生研究院 (NIH) 於 2025 年 10 月發表的一項題為《藥劑師參與丙型肝炎管理》的研究表明，這種模式能夠有效地彌合從診斷到治療啟動之間的差距。藥劑師主導的措施實現了 66.5% 的治療啟動率，顯著高於傳統的轉診方式。透過簡化患者體驗，這種方法提高了患者的用藥依從性，並擴大了高發生率地區的市場覆蓋範圍。

同時，數位化檢測治療平台的普及應用正在加速市場滲透，透過虛擬醫療互動解決地域隔離問題。這些整合的遠距醫療系統使醫療服務提供者能夠遠距診斷病情並開立處方，從而免去了服務不足地區患者前往實體診所就診的需要。奧勒岡健康與科學大學2024年11月發布的一份題為《遠端醫療結合社區同儕支持可提高農村地區丙型肝炎患者的治療成功率》的報告，清晰地展現了其對難以觸及人群的影響。報告顯示，接受遠端醫療服務的患者中有85%成功註冊治療，而對照組的比例僅為12%。如此高的接受率表明，數位化平台對於刺激醫療設施匱乏地區的需求至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球C型肝炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（急性C型肝炎、慢性C型肝炎、其他）
    • 治療方法（抗病毒藥物、疫苗、免疫調節藥物、手術、其他）
    • 透過診斷（切片檢查、血液檢查、影像檢查、其他）
    • 依給藥途徑（口服、注射、其他）
    • 通路（醫院藥房、零售藥房、網路藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美C型肝炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲丙型肝炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區丙型肝炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲C型肝炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美丙型肝炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球C型肝炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company B

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23902

The Global Hepatitis C Market is projected to expand from USD 9.32 Billion in 2025 to USD 13.15 Billion by 2031, reflecting a compound annual growth rate of 5.91%. This sector encompasses the manufacturing and distribution of diagnostic tools and therapeutic agents, specifically Direct Acting Antivirals utilized to manage and eradicate hepatitis C infections. The market's upward trajectory is primarily fueled by the rising global disease burden and international directives for viral elimination, which promote government-sponsored screening and treatment programs. Furthermore, the safety and high success rates of modern antiviral regimens enhance patient compliance and broaden the treatable demographic, addressing the needs of the 50 million individuals reported by the World Health Organization in 2024 to be living with chronic hepatitis C.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.32 Billion
Market Size 2031USD 13.15 Billion
CAGR 2026-20315.91%
Fastest Growing SegmentChronic Hepatitis C
Largest MarketNorth America

Despite these positive indicators, the market encounters substantial obstacles due to the prohibitive costs of advanced therapies, which limit availability in developing nations with high price sensitivity. This financial hurdle is compounded by low rates of diagnosis, as inadequate healthcare infrastructure in these areas fails to identify asymptomatic carriers. Consequently, a significant number of infected individuals remain without treatment, a situation that prevents the market from reaching its full potential and decelerates global elimination initiatives.

Market Driver

The execution of Government-Led Disease Elimination Programs acts as a crucial market catalyst, with nations implementing strategies to align with international health objectives. These extensive public health structures require significant procurement of diagnostics and medications, establishing a reliable commercial channel for industry participants. The United Kingdom exemplifies success in this area, proving the effectiveness of state-managed efforts; the Viral Hepatitis Prevention Board's November 2024 analysis in the 'HCV in England report 2024' indicates that the national elimination strategy reduced hepatitis C-related mortality to 0.41 per 100,000 people, exceeding World Health Organization targets and demonstrating the value of funded interventions.

Complementing these policies, the broad uptake of Advanced Direct-Acting Antiviral Therapies propels market expansion by facilitating rapid and effective cures for diagnosed patients. The superior safety profile and simplified dosing schedules of these modern treatments have markedly enhanced linkage-to-care statistics, resulting in increased treatment volumes worldwide. This demand is highlighted by the British Liver Trust's April 2025 'Hepatitis C in England 2024' report, which noted that 96.1% of diagnosed individuals connected to care began treatment. Nevertheless, the global disease burden remains a primary driver of demand; the Centers for Disease Control and Prevention reported in their July 2025 'Global Viral Hepatitis' update that approximately 1 million new infections occurred globally in the previous year, emphasizing the persistent need for market solutions.

Market Challenge

The substantial acquisition costs associated with advanced antiviral therapies act as a major constraint on market growth, especially within developing economies where healthcare resources are scarce. These elevated pricing models often surpass the financial limits of public health systems and individual patients, thereby restricting the quantity of treatments distributed. Such economic barriers hinder the market's ability to leverage the high disease prevalence in these regions, leading to significant revenue forfeiture and restricted market entry in areas that otherwise demonstrate a strong need for medical intervention.

Additionally, the absence of robust healthcare infrastructure aggravates this challenge by impeding the identification of the infected population. Insufficient diagnostic capabilities mean that a vast number of patients remain unaware of their condition, preventing them from accessing essential therapies. According to the World Health Organization, only 36% of individuals living with hepatitis C worldwide were diagnosed in 2024. This substantial diagnosis gap effectively diminishes the size of the addressable market, as the majority of potential candidates for therapeutic agents remain undetected and untreated, which directly stalls overall market expansion.

Market Trends

The Decentralization of Care to Community Pharmacies is reshaping service delivery by moving treatment initiation from centralized hospitals to readily accessible local drugstores. This trend helps overcome infrastructure limitations by enabling pharmacists to administer screenings and prescribe direct-acting antivirals, effectively engaging patients who might otherwise be lost in traditional care pathways. The National Institutes of Health's October 2025 study, 'Pharmacist Involvement in Hepatitis C Management,' validates the efficacy of this model in bridging the gap between diagnosis and cure, revealing that pharmacist-led initiatives achieved a therapy initiation rate of 66.5%, which is significantly higher than standard referral methods. By streamlining the patient experience, this approach improves adherence and broadens the market reach within high-prevalence communities.

Concurrently, the Adoption of Digital Test-to-Treat Platforms is increasing market penetration by resolving issues of geographical isolation through virtual healthcare interactions. These integrated telemedicine systems enable providers to diagnose conditions and prescribe curative treatments remotely, eliminating the need for physical clinic visits in underserved areas. The impact on engaging hard-to-reach populations is evident in Oregon Health & Science University's November 2024 report, 'Telehealth plus local peer support boosts treatment success for hepatitis C in rural patients,' which found that 85% of patients referred to telehealth services successfully enrolled in treatment compared to just 12% in the control group. This high uptake demonstrates that digital platforms are essential for stimulating demand in regions lacking adequate medical facilities.

Key Market Players

  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company B

Report Scope

In this report, the Global Hepatitis C Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis C Market, By Type

  • Acute Hepatitis C
  • Chronic Hepatitis C
  • Others

Hepatitis C Market, By Treatment

  • Antiviral Drugs
  • Vaccine
  • Immune Modulator Drugs
  • Surgery
  • Others

Hepatitis C Market, By Diagnosis

  • Liver Biopsy
  • Blood Tests
  • Imaging Tests
  • Others

Hepatitis C Market, By Route of Administration

  • Oral
  • Parenteral
  • Others

Hepatitis C Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hepatitis C Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis C Market.

Available Customizations:

Global Hepatitis C Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hepatitis C Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Acute Hepatitis C, Chronic Hepatitis C, Others)
    • 5.2.2. By Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others)
    • 5.2.3. By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others)
    • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Hepatitis C Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Diagnosis
    • 6.2.4. By Route of Administration
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis C Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Diagnosis
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Hepatitis C Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Diagnosis
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Hepatitis C Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Diagnosis
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Distribution Channel

7. Europe Hepatitis C Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Diagnosis
    • 7.2.4. By Route of Administration
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatitis C Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Diagnosis
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Hepatitis C Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Diagnosis
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Hepatitis C Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Diagnosis
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Hepatitis C Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Diagnosis
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Hepatitis C Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Diagnosis
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Hepatitis C Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Diagnosis
    • 8.2.4. By Route of Administration
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hepatitis C Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Diagnosis
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Hepatitis C Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Diagnosis
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Hepatitis C Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Diagnosis
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Hepatitis C Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Diagnosis
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Hepatitis C Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Diagnosis
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Hepatitis C Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By Route of Administration
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hepatitis C Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Diagnosis
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Hepatitis C Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Diagnosis
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Hepatitis C Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Diagnosis
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Distribution Channel

10. South America Hepatitis C Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Diagnosis
    • 10.2.4. By Route of Administration
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hepatitis C Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Diagnosis
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Hepatitis C Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Diagnosis
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Hepatitis C Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Diagnosis
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hepatitis C Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Mylan N.V.
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Bayer AG
  • 15.7. Merck & Co., Inc.
  • 15.8. F. Hoffmann-La Roche AG
  • 15.9. Bristol-Myers Squibb Company B

16. Strategic Recommendations

17. About Us & Disclaimer